Lilly’s retatrutide beats Ozempic in a diabetes trial (not approved) Lilly announced that its investigational once-weekly drug retatrutide, tested against Ozempic 2 mg in 1,298 adults with type 2 diabetes, led to average weight loss of 19.5% (9 mg) and 20.9% (12 mg) at 80 weeks, versus 9.4% on Ozempic. A1C fell 2.2 points versus
The short answer: Early, company-sponsored analyses suggest that semaglutide and tirzepatide nudge some blood-based “aging clock” readings in a younger direction in people with obesity, heart disease or diabetes. These results are not peer reviewed, none of them tested healthy people, and a better clock reading has not been shown to mean a longer or
Bottom Line On October 28, 2026, Eli Lilly announced topline results from TRANSCEND-T2D-2, a Phase 3 trial of 1,298 adults with type 2 diabetes. After 80 weeks, people taking its investigational drug retatrutide lost about 19.5% (9 mg dose) to 20.9% (12 mg dose) of their body weight and lowered HbA1C by 2.2 percentage points,
